REMEDi4ALL’s Post

“Simply put, fine-tuning a model that was originally trained on hundreds of millions of natural #sequences using merely dozens to hundreds of labeled examples is difficult. It is therefore imperative to gather more data relevant to the engineering of #protein #therapeutics.” 👩🏾💻 Love this #openaccess review in Cell, by an amazing Amgen team. Though the focus is on “generative #biology”, in reality the central tenet matches with TetraScience’s - better data leads to better models leads to improved #DMTA cycles. 🔄🌀 “…different large data sources will need to become #interoperable (i.e., annotated and standardized).” Calls for improvements to public DBs, adoption of #federatedlearning, and reference to emerging #modalities like nanobodies round out this wide-ranging (yet succinct!) review. Have a look; it’s 30 mins well spent. 🙌🏽 😉 For the 2024 paper: https://lnkd.in/e22kJbxF

"The use of microsampling plays an important role in decreasing the patient burden. The setting in which the samples are taken is also important to consider. Who will perform the sampling? Are the patients neonates or adults? Although easy and painless sampling is very beneficial for the patient, a high-quality sample is also important for the quality of data." -- Remco Koster, PhD, Associate Director, Bioanalytical Science, ICON plc. 🩸 For more insights from Dr. Koster on the bioanalysis of remotely collected #microsamples for #research and #clinicaltrials, listen to the #podcast or read the full transcript here: 👇 #bloodsamples #remotespecimencollection #Mitra #VAMS #microsampling #bioanalysis #ScienceThatBenefitsPeople Trajan Scientific and Medical https://hubs.la/Q02jSbqy0

𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐢𝐧 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 In her groundbreaking article featured in "𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐬𝐢𝐚, 𝐌𝐚𝐠𝐚𝐳𝐢𝐧𝐞 𝐈𝐬𝐬𝐮𝐞 𝟓𝟔," Gulnaz Zaidi, Bioinformatics Scientist at miBiome Therapeutics LLP, explores how precision medicine is transforming patient care. By leveraging genetic and lifestyle information, precision medicine tailors treatment and prevention strategies to individual needs. Genomics research plays a pivotal role in this evolution, providing enhanced genetic testing and aiding in 𝐝𝐫𝐮𝐠 𝐭𝐚𝐫𝐠𝐞𝐭 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲. Imagine a future where treatments are as unique as our DNA! 𝐉𝐨𝐢𝐧 𝐭𝐡𝐞 𝐜𝐨𝐧𝐯𝐞𝐫𝐬𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐡𝐨𝐰 𝐠𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐢𝐬 𝐬𝐡𝐚𝐩𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞. 🔗 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐡𝐞𝐫𝐞: https://lnkd.in/g-cGRqvw 𝐕𝐢𝐬𝐢𝐭 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://lnkd.in/dxkGndFf 𝐒𝐭𝐚𝐲 𝐮𝐩𝐝𝐚𝐭𝐞𝐝 𝐰𝐢𝐭𝐡 𝐨𝐮𝐫 𝐥𝐚𝐭𝐞𝐬𝐭 𝐜𝐨𝐧𝐭𝐞𝐧𝐭 𝐛𝐲 𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐢𝐧𝐠 𝐡𝐞𝐫𝐞: https://lnkd.in/ghDSEXKj 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐨𝐮𝐫 𝐌𝐚𝐠𝐚𝐳𝐢𝐧𝐞 𝐈𝐬𝐬𝐮𝐞𝐬: https://lnkd.in/eBQD_FfQ 𝐈𝐧𝐭𝐞𝐫𝐞𝐬𝐭𝐞𝐝 𝐢𝐧 𝐚𝐝𝐯𝐞𝐫𝐭𝐢𝐬𝐢𝐧𝐠 𝐰𝐢𝐭𝐡 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐬𝐢𝐚? 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐨𝐮𝐫 𝐦𝐞𝐝𝐢𝐚 𝐩𝐚𝐜𝐤 𝐡𝐞𝐫𝐞: https://lnkd.in/dbaBPC8E #genomics #precisionmedicine #bioinformatics #healthcareinnovation #mibiometherapeutics #genetictesting #drugdiscovery #pharmafocusasia #personalizedmedicine #futureofhealthcare #patientcare #medicalresearch #pharmafocus #healthtech #pharmaceuticals #magazine

#ScienceFridays 🔬 Research paper of the week ➡ ‘Identifying patterns to uncover the importance of biological pathways on known drug repurposing scenarios’ 🔎 Abstract: Drug repurposing plays a significant role in providing effective treatments for certain diseases faster and more cost-effectively. Successful repurposing cases are mostly supported by a classical paradigm that stems from de novo drug development, based on the “one-drug-one-target-one-disease” idea. In this article, the authors investigated the use of biological pathways as potential elements to achieve effective drug repurposing. ✍️ Authors: Belén Otero Carrasco, Esther Ugarte Carro, Lucía Prieto Santamaría, Marina Díaz Uzquiano, Juan Pedro Caraça-Valente Hernández and Alejandro Rodríguez González. 🏫 Affiliations: CTB-UPM Centro de Tecnología Biomédica and ETS de Ingenieros Informáticos, in collaboration with Medical Data Analytics Laboratory (MEDAL). 🔗 Full article published on BMC Genomics: https://lnkd.in/e2EXzWda For more articles like this, check out our #DrugRepurposing Research Collection curated via ScienceOpen 💊 https://lnkd.in/eckmMnZY #PharmaInnovation #DrugResearch #AIinMedicine #FutureOfMedicine

Happy to share my article "Genomics in Precision Medicine" published in the magazine Pharmafocus Asia, where I share my thoughts on genomics changing the paradigm of disease management! Special thanks to Harry Callum and Pharma Focus Asia Magazine

Reproducibility matters! “If you publish something that’s not reproducible, it's negatively impacting drug discovery. It's not going to create therapies for any patient.” Read my full comments along with other experts in the field in this SLAS article.

There is a common perception that more data inherently leads to better outcomes, which may be accurate in the context of sociological data. However, for high-precision medical and clinical data, it is crucial to have data from well-controlled experiments with meticulous data collection. Recreational genomics products, such as 23andMe, do not likely meet these rigorous standards. A similar perception is now emerging with the application of large language models (LLMs) to genomics and proteomics data. https://lnkd.in/gaH9WY83

One small detail makes all the difference between a reproducible experiment and one that is not, according to Robert Campbell, Ph.D., editor-in-chief of SLAS Discovery: Advancing the Science of Drug Discovery. Campbell comments in a recent SLAS Electronic Laboratory Neighborhood article that reproducibility is rooted in appropriate experimental design, well-described methods, and inclusion of all pertinent details – particularly when scientists enter the publishing process. In the same article, Kenda LJ Evans, Ph.D., of Agilent Technologies (Santa Clara, CA, USA), and co-chair for the SLAS Screen Design and Assay Technology Topical Interest Group (TIG), comments: “The challenges of reproducibility are not going to go away. We need it when we’re making go/no-go decisions. If you don’t have good reproducibility, it’s hard to know what’s a true result and what’s a false-positive. I think that talking about reproducibility and finding better ways of achieving it in our assays is crucial to drug discovery and research.” Read what other subject matter experts have to say in the article: https://lnkd.in/gNEspcne.

Key Milestone Achieved: We are thrilled to announce that we have completed the AI-driven generation and optimization of small molecules as potent GABA-A agonists. 🎉 This achievement reflects our commitment to advancing drug discovery through a systematic and rigorous approach. Here is a glimpse into our process: 1. Data Cleaning: Ensured our dataset is robust and reliable. 2. Protein Finding: Identified 12 relevant protein structures for our studies. 3. Molecule Generation: Created potential molecular candidates; 2000 to 4000 valid potential molecules were generated. 4. Molecular Properties Generation: Generated 22 properties from SMILES through our in-house AI-generation models, narrowing down 250 to 350 molecules for the next process. 5. QSAR: Employed quantitative structure-activity relationship models for enhanced insights, achieving an overall average testing accuracy of 80% for the QSAR model testing. 6. Toxicity: Our in-house model evaluated the safety profiles of our candidates for hepatotoxicity, mutagenicity, cardiotoxicity, carcinogenicity and nephrotoxicity. 7. Docking and Interactions: Shortlisted non-toxic molecules for docking study. 8. Molecule Similarity Check and Shortlisting: Narrowed down our candidates to the most promising molecules based on docking and similarity score checked. This accomplishment reflects our dedication to cutting-edge research and collaboration, propelling us toward impactful solutions in neuroscience. A huge thanks to our team and partners for their hard work and dedication! #DrugDiscovery #MolecularBiology #GABAA #Pharmaceuticals #Innovation #Research #Science #Biotechnology #QSAR #LifeSciences #BiomedicalResearch #PharmaTech #DrugDevelopment #Bioinformatics #HealthTech #ClinicalTrials #Pharmacology #TargetedTherapy #SustainableScience #ArtificialIntelligence #MachineLearning #AIinResearch #AIDrugDiscovery #AIinBiotech #DataScience #PredictiveModeling #SmartHealth #DigitalHealth

AI is the way of the future & it’s happening now! You can see it being integrated all over the internet, in platforms & systems … You better get onboard, otherwise you’ll be left behind! Here is one great example: #AI #AIdriven #drugdesign #FutureAI